Update to Diabetes Mellitus Type 2

18 Oct Update to Diabetes Mellitus Type 2

All TreatGx users now have access to the updated treatment algorithm for Diabetes Mellitus Type 2.

Diabetes Mellitus Type 2 

This comprehensive update accounts for revisions made to existing clinical guidelines that will help health care providers select the safest and most effective medications with their patients. This update follows the recommendations from the American Diabetes Association Standards of Medical Care in Diabetes 2021 [1], Diabetes Canada 2020 Update [2], and the American Association of Clinical Endocrinologists and American College of Endocrinology 2020 executive summary [3].  

A key update is the addition of a feature to show all insulin options, to help make insulin initiation or optimization more efficient for healthcare providers. All non-insulin options will be shown regardless of current medications if the option to “show insulin options” is not selected. Insulin degludec, rosiglitazone, and lixisenatide have been added as new medication options. 

As always, this update includes the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, and drug interactions. 

References

1. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021.Diabetes Care2021, 44(Suppl 1):S111-s124. 
2. Lipscombe L, Butalia S, Dasgupta K, Eurich DT, MacCallum L, Shah BR, Simpson S, Senior PA:Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update.Canadian journal of diabetes 2020, 44(7):575-591. 
3. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, Blonde L, Bush MA, DeFronzo RA, Garber JRet al:CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2020 EXECUTIVE SUMMARY. Endocr Pract 2020, 26(1):107-139.